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Summary: We have developed a novel, rapid microassay for dichloroacetate in the serum. The serum sample is
directly injected into a gel-permeation high-performance liquid chromatography apparatus. The peak of dichlo-
roacetate appears after a giant protein peak. The method requires a very small amount of serum (10 ), and the
analysis time is short (20 min). Using this micro method, we measured the serum concentrations of dichloroacetate
in healthy adult volunteers and paediatric patients with congenital lactic acidosis. Although the effect of dichlo-
roacetate on the neurological manifestations of congenital lactic acidosis has not been proved to be beneficial, the
potential usefulness of dichloroacetate in refractory lactic acidosis in cardiac and respiratory failure has been
recognized, and human äs well äs animal studies have been undertaken in many laboratories. To prevent possible
side effects of dichloroacetate, it has been recommended that the minimal effective dose be used. Our microassay
method is useful for both human and animal experiments, even after administration of minimal doses.
Introduction
Dichloroacetate äs the sodium salt has been used for the
treatment of hyperglycaemia, lactic acidosis, and hyper-
cholesterolaemia (1—7). Although dichloroacetate has
many metabolic effects on glucose, lipid and amino acid
metabolism, its main pharmacologic effect has been
shown to be the activation of the pyruvate dehydrogen-
ase1) complex by inhibiting pyruvate dehydrogenase ki-
The clinical usefulness of dichloroacetate has been ham-
pered by its possible toxic and mutagenic effects (7).
Peripheral neuropathy and testieular atrophy have been
reported in humans äs well äs animals after chronic ad-
ministration of dichloroacetate (12). Recently, however,
dichloroacetate has been reevaluated in response to the
many reports on its efficacy in the refractory acidosis
encountered in emergency medicine, such äs cardiac ar-
rest and septic shock (13 — 15).
Although there have been few reports on the acute tox-
icity of dichloroacetate, it has been recommended that
the minimal effective dose be used in order to prevent
possible adverse effects (7). Dichloroacetate has been
measured by gas-chromatography (11), but the measure-
ment is time-consuming and requires 2 ml of blood. Be-
cause of these technical difficulties, blood concen-
trations of dichloroacetate have not been routinely meas-
ured.
In the present study, we have developed a rapid micro-
method for dichloroacetate measurement using gel per-
meation chromatography. With this micromethod, we
have investigated the pharmacokinetics of dichloroacet-
ate by measuring its level in serum in various patients
with lactic acidosis, äs well äs in healthy adult volun-
teers. Since the new method requires a very small am-
ount of serum (10 ), and needs no extraction procedure
for sample preparation, it is suitable for measuring
serum concentrations of dichloroacetate in human äs
well äs animal experiments.
!) Enzymes:
Pyruvate dehydrogenase, EC 1.2.4.1; Pyruvate dehydrogenase kin-
ase, EC 2.7.1.99.
Materials and Methods
Dichloroacetate (sodium salt) was purchased from Tokyo Kasei
(Tokyo). The other cheraicals were of the highest quality available
and obtained frorn Standard sources.
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 32, 1994 / No. 2
80 Sakakihara et al.: Microassay for dichloroacetate by gel-permeation chromatography
Blood samplcs were drawn from patients with lactic acidosis of
various actiologies and from normal adult volunteers. The basic
disorders of thc patients and doses of dichloroacetate are summar-
ized in table 1. Informed consent was obtained from the parents of
thc patients betöre dichloroacetate administration. The volunteers
werc given 35 mg/kg of dichloroacetate orally. Blood samples were
drawrfbeforc and after oral dichloroacetate loading at 30 minutes
intervals. Serum was separated immediately and kept frozen at
-20 °C until analysis.
A small amount (15 to 25 ) of serum was directly injected into
a high-performance liquid chromatography (HPLC) apparatus. A
gel-permeation HPLC column (Asahipak GS-320, Asahi Kasei, To-
kyo) was equipped with a pump (Waters, Model 6000A) and UV
spectrophotometer (Soma UV detector, Soma Kogaku, Tokyo). The
column was eluted with 0.01 mol/1 ammonium acetate (pH 4.0)/
acetonitrile (9+1, by vol.) at a flow rate of 2.0 ml/min, and the
eluate was monitored at 220 nm. The quantitation of dichloroacet-
ate was carried out by comparing the peak height of dichloroacetate
with the calibration curve constructed by plotting the peak heights
of various known amounts of dichloroacetate.
Dichloroacetate was also measured by gas-chromatography accord-
ing to the method of Wells et al. (11) with trichloroacetic acid äs
the internal Standard.
Results
The new Chromatographie method of
dichloroacetate measurement
The chromatogram of normal serum is shown in figure
l a. In the gel-permeation column, molecules whose
sizes are greater than Mr 40 000 are excluded from the
column bed, and the smaller molecules are retained in
the column for various times according to the interaction
between the molecules and the packing material. Thus
the chromatogram of normal serum consists of a giant
peak which represents the serum components with mol-
ecular mass greater than 40000 (mostly proteins) and
several unknown peaks following it. The chromatogram
of the serum from a volunteer after dichloroacetate in-
take is shown in figure Ic. As shown in the figures, a
distinct peak appeared at 12.2 min. A peak with exactly
the same retention time was observed when serum pre-
Tab.l
Pa-
tient
No.
1
2
3
4
Profiles
Age
(a)
8 5/12
3 8/12
8 6/12
9/12
of the patients.
Sex Diagnosis
$ Pyruvate dehydrogenase
complex deficiency
S Pyruvate dehydrogenase
complex deficiency
? Mitochondrial encephalo-
pathy, lactic acidosis and
stroke-like episode
(MELAS)
? Leigh encephalopathy
Dose of
dichloro-
acetate
(mg/kg · d)
80
40
30
30
10 20 0 10
Retention time [min]
20
V
10 20 0 10
Retention time [min]
20
Fig. l Chromatograms of dichloroacetate in serum.
(a) Chromatogram of normal serum. Note the giant peak irnmedir
ately after the solvent peak.
(b) Chromatogram of normal serum mixed with authentic dichlo-
roacetate.
(c) Chromatogram of the serum of a volunteer after a single oral
dichloroacetate load.
(d) Chromatogram of the serum from Patient 1.
viously supplemented with authentic dichloroacetate
was analysed (fig. Ib). The chromatogram of serum
from Patient l is shown in figure Id. The calibration
curve constructed by injecting various known amounts
of authentic dichloroacetate showed a linear relation'be-
tween 0 to 500 mg/1 äs shown in figure 2. The minimal
ineasurable concentration was 5 mg/1 when 25 of
serum was injected, but a much lower coricenträtion was
measurable by increasing the amount injected, orby in-
creasing the sensitivity of the UV detector. To assess
the reproducibility of the method, we injected replicate
aliquots of the sample. The coefficient of Variation (CV)
was found to be very small (CV = 2.4%, n = 8).
We measured the levels of dichloroacetate in 9 serum
samples by conventional gas chromatography concomi-
i:
l
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Fig. 2 Calibration curve of dichloroacetate. Serum samples with
known concentrations of dichloroacetate (10, 50, 100, 200 mg/1)
were prepared by adding authentic dichloroacetate to serum from
a healthy adull volunteer. A 25 μΐ aliquot of each sample was in-
jected into HPLC. Good linearity was obtained between 10 to 200
mg/1 (y = 0.04x + 0.045, r = 0.997).
tantly with the new micromethod (l 1). As shown in fig-
ure 3, there was a good correlation between the results
obtained from the two methods.
Finally, the specificity of the method was ascertained
by injecting the sera from 10 patients who were taking
different drugs (antiepileptic drugs, antibiotics) into the
HPLC. No peaks were observed around the retention
time of the dichloroacetate peak (data not shown).
Pharmacokinetics of dichloroacetate in
healthy adult volunteers
Using the micromethod, we investigated the pharmaco-
kinetics of dichloroacetate in healthy adults. The time
course of the levels of dichloroacetate in two volunteers
is shown in figure 4. The dichloroacetate was absorbed
quickly and reached a peak concentration within 30—60
minutes. The level then dropped rapidly, and by 5 hours
dichloroacetate had disappared from the serum. The half
life of dichloroacetate eliminatipn from the serum was
calculated to be around 30 min by the rnodified method
of Wagner & Nelson (16).
S %QO
250
200
150
100
50
50 100 150 200 250
Dichloroacetate [mg/1]
Gel-permeation chromatography
Fig. 3 Correlation between the new micromethod and gas chrom-
atography. A good correlation was obtained between the two me-
thods (y = 1.07x - 0.74, r « 0.992).
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Fig. 4 Concentrations of dichloroacetate in the sera from healthy
adult volunteers after a single oral dose of dichloroacetate (35 mg/
kg). The half lives of elimination are 0.534 h (-D-) and 0.573 h
(-0-).
Measurement of serum dichloroacetate levels
in patients
The typical time course of serum dichloroacetate con-
centrations is shown in figures 5a and 5b. In patients l,
2 and 3, dichloroacetate had been orally administrated
for various periods previously. In Patients 2, 3 and 4, the
attained peak levels of dichloroacetate were different,
100 200 300
Time [min]
400
125
^100-
I
50-
25-
S
100 200 300 400 500 600
Time [min]
Fig. 5 Concentrations of dichloroacetate in the sera from the
patients.
(a) Patient l (-·-)
(b) Patients 2 (-O-), 3 (-·-), and 4 (-O-).
In Patients l, 2 and 3, dichloroacetate had already been adminis-
tered for various times before the measurements. Thus the levels of
dichloroacetate before oral administration (at time 0) were not zero.
The half-lives of dichloroacetate for Patients l, 2, and 3 were
245 h, 0.18 h and 0.87 h respectively.
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although the doses of dichloroacetate per body weight
were similar. It was also shown that the ratio of dose to
blood level was not linear, äs indicated by the very high
levels of dichloroacetate in Patient 1. The very pro-
longed half-life of dichloroacetate in Patient l suggests
an impaired elimination of dichloroacetate from the cir-
culation in this case.
Discussion
We demonstrated that the micromethod for dichloroacet-
ate measurement is useful for monitoring serum dichlo-
roacetate. Once the HPLC apparatus was set up, it usu-
ally took only 20 minutes to obtain the results. In the
conventional gas-chromatographic method, it would
take at least several hours, since deproteinization and
derivatization of dichloroacetate must be performed be-
fore the Chromatographie measurement (11). Addition of
internal Standard is also required in the gas^chromato-
graphic method. Furthermore, the new method requires
much less sample: the gas-chromatographic method re-
quires l ml of serum, whereas äs little äs 10 is enough
for the micro method. The serum contained in a glass
capillary is sufficient for the measurement of dichlo-
roacetate by the new method. We are therefore able to
monitor dichloroacetate concentrations even in small
animals.
The pharmacokinetics of dichloroacetate determined by
the micro method are comparable with the previously
reported values obtained with a single intravenous injec-
tion (5, 11, 17, 18). Although the accurate calculation of
the half-life was difficult when the drug was admini-
strated orally, we estimated the approximate half life of
dichloroacetate by a modified calculation method of
Wagner & Nelson (16). In healthy adults, the half-life
was approximately 30 minutes, although the calculated
half-life of dichloroacetate was much longer than this in
Patient 1. It has been reported that the elimination of
dichloroacetate from the circulation follows Saturation
kinetics (11), and tissue accumulation of dichloroacetate
occurs when dichloroacetate is administered for a long
time. Adverse effects such äs polyneuropathy and tes-
ticular atrophy have been reported after chronic dichlo-
roacetate treatment in human and animal studies (7, 12).
Cönsidering the unpredictability of exact blood levels of
diehloroacetate, it is pertinent to measure them in
pätients treated with dichloroacetate. The fact that
dichloroacetate therapy has not yet been accepted äs a
Standard therapy for lactic acidosis is mainly due to its
possible toxic side-effects. It is important to maintain
the reported minimum therapeutic level (130 mg/1) of
dichloroacetate (11). Although it is undoubtedly effec-
tive in lowering blood lactate and pyruvate in pätients
with congenital lactic acidosis, it has been reported to
show little effect in improving existing neurologic
Symptoms (7). Recently, however, its potential clinical
usefulness has been reappraised, especially in critical
care medicine (13 — 15). It has been demonstrated that
dichloroacetate is effective in correcting severe acidosis
refractoiy to the conventional sodium bicarbonate ad-
ministration. It has also been shown that it has a protec-
tive effect against myocardial ischaemic damage. To
confirm its potential clinical usefulness, many labora-
tories have been eonducting animal experiments to de-
termine its efficacy and safety. Our micromethod is suit-
able for monitoring blood dichloroacetate concentrations
in animal experiments äs well äs in clinical trials.
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